Insulin and Glucagon Pharmacology: Mechanisms, Preparations and 2026 Diabetes Care

Medical education review — 10 November 2026. Not a substitute for individualized diagnosis, prescribing advice or local guidance.

Overview

Insulin and glucagon maintain glucose homeostasis through opposing actions. Insulin is indispensable for type 1 diabetes and often required for type 2 diabetes; glucagon is a rescue treatment for severe hypoglycemia. Contemporary care integrates continuous glucose monitoring (CGM), automated insulin delivery where appropriate, and accessible rescue glucagon [1, 2, 3].

Mechanisms

Insulin is a two-chain peptide hormone acting on a receptor tyrosine kinase. Activation of IRS–PI3K–Akt pathways promotes GLUT4 translocation in muscle and adipose tissue, glycogen and lipid synthesis, and suppression of hepatic glucose output. Glucagon is a 29-amino-acid peptide activating hepatic Gs-coupled receptors, increasing cAMP/PKA signaling, glycogenolysis and gluconeogenesis. Its glycemic efficacy may be limited when glycogen stores are depleted [1].

Insulin preparations

  • Rapid-acting prandial: lispro, aspart, glulisine and faster formulations; timing varies by product.
  • Short-acting: human regular insulin; IV regular insulin is used in supervised hyperglycemic emergencies.
  • Intermediate: NPH, with a discernible peak and higher nocturnal hypoglycemia risk than flatter basal analogues.
  • Long-acting basal: glargine and other marketed analogues, with formulation-dependent duration.
  • Ultra-long-acting: degludec; specific weekly insulin products may be approved in some jurisdictions, but availability and indication must be confirmed locally.
  • Premixed preparations: combine basal/intermediate and mealtime components, trading dosing simplicity for reduced flexibility.

PK/PD and administration

Most insulin preparations are administered subcutaneously. Injection-site blood flow, lipohypertrophy, exercise, dose and formulation affect absorption; rotate sites and do not interchange insulin concentrations or pens without professional review. Renal impairment may decrease insulin clearance. Basal–bolus regimens, pumps and automated insulin delivery should reflect meal intake, glucose patterns and hypoglycemia risk rather than a universal fixed dose [1, 2].

Glucagon rescue formulations

For severe hypoglycemia when the person cannot safely swallow, commercially available treatments include intranasal glucagon and ready-to-inject subcutaneous glucagon, as well as reconstitution kits. Ordinary oral glucagon tablets are not an established rescue formulation. Do not give food, drink or glucose orally to an unconscious person. Seek emergency assistance, position safely, administer prescribed glucagon promptly and monitor response. ADA 2026 recommends prescribing glucagon to insulin users and others at high risk and training caregivers; preparations not requiring reconstitution are preferred [2, 3].

How to respond to a low glucose reading

For an alert adult who can swallow safely, a usual first step is 15 g of fast-acting carbohydrate. Recheck glucose after 15 minutes and repeat if it remains below 70 mg/dL (3.9 mmol/L). Young children may need a smaller amount under their individual plan. Once the low has resolved, a meal or snack can help prevent recurrence. [4]

If the person is unconscious, having a seizure or unable to swallow safely, keep food and drink out of the mouth. Give the prescribed rescue glucagon and call emergency services immediately. Injectable products and nasal powder are available. The nasal dose does not require the person to inhale. Turn an unconscious person onto their side. Once awake and swallowing safely, give oral carbohydrate. Glucagon can be ineffective after prolonged starvation, and emergency clinicians may need to give glucose intravenously. [4, 5]

Adverse effects and monitoring

Insulin causes hypoglycemia, weight gain and possible lipodystrophy or hypokalemia. Excess dosing, missed meals, activity and alcohol may precipitate hypoglycemia. Glucagon can cause nausea/vomiting and is not a substitute for emergency evaluation when recovery is incomplete. Review HbA1c, CGM metrics, kidney function, insulin technique and access to rescue treatment [2, 3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S009. Available from: https://doi.org/10.2337/dc26-S009
  3. American Diabetes Association Professional Practice Committee. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S006. Available from: https://doi.org/10.2337/dc26-S006
  4. Centers for Disease Control and Prevention. Treatment of low blood sugar (hypoglycemia). [cited 2026 Nov 10]. View source.
  5. US Food and Drug Administration. Baqsimi (glucagon nasal powder). Prescribing information. 2025. [cited 2026 Nov 10]. View source.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *